Life Sciences Archives - EverGlade Consulting

Life Sciences

PROSPR program

Proactive Solutions for Prolonging Resilience Opportunity Announcement

Leave a Comment / All Posts, ARPA-H, Life Sciences / By

The Foci of PROSPR ARPA-H-SOL-25-125, PROSPR The PROSPR solicitation outlines a comprehensive, multi-year program structured around the development, validation, and deployment of novel health technologies. The program is divided into three primary technical areas (TAs), each addressing a critical component of healthspan extension: TA1 focuses on developing a PROSPR Intrinsic Capacity (IC) score that quantifies […]

Proactive Solutions for Prolonging Resilience Opportunity Announcement Read More »

organophosphorus nerve agents

Project UPREG

Leave a Comment / All Posts, DTRA, Life Sciences / By

Project UPREG for Draft SOO Release Project UPREG: DTRA’s Push for Enhanced Protection Against Nerve Agents The Defense Threat Reduction Agency’s (DTRA) Chemical and Biological Technologies Department, in its role as the Joint Science and Technology Office (JSTO), has launched Project UPREG, a bold initiative to develop next-generation medical countermeasures against organophosphorus nerve agents (OPNAs).

Project UPREG Read More »

ARPA-H_Mission Office Innovative Solutions Openings (ISO)

ARPA-H Mission Office Innovative Solutions Openings (ISOs)

Leave a Comment / All Posts, ARPA-H, Life Sciences / By

Overview The Advanced Research Projects Agency for Health (ARPA-H) is dedicated to accelerating transformative health solutions by tackling some of the most pressing challenges in biomedical and healthcare innovation. As part of this mission, ARPA-H has launched Mission Office Innovative Solutions Openings (ISOs) that promote the development of health technologies that lie outside of the

ARPA-H Mission Office Innovative Solutions Openings (ISOs) Read More »

NIH resume issuing grants

NIH Admits Funding Freeze Was Illegal, Resumes Issuing Grants

Leave a Comment / All Posts, Life Sciences, NIH / By

Overview In a major development for the biomedical research community, the National Institutes of Health (NIH) has officially acknowledged that its recent funding freeze was unlawful and has announced the resumption of grant distributions. This decision follows weeks of controversy and legal challenges, during which research institutions, universities, and lawmakers criticized the abrupt halt in

NIH Admits Funding Freeze Was Illegal, Resumes Issuing Grants Read More »

ARPA-H_RAPID rare disease diagnostics

RAPID Solicitation

Leave a Comment / All Posts, ARPA-H, Life Sciences / By

RAPID_SOL_25_119_FINAL Overview The Advanced Research Projects Agency for Health (ARPA-H) recently announced the newly approved program for Rare disease AI/ML for Precision Integrated Diagnostics (RAPID). The RAPID program aims to significantly improve outcomes for people with rare diseases by reducing diagnostic delays by ≥50%, decreasing misdiagnosis rates, and expanding access to diagnostics. Beyond benefitting the treatment experience of

RAPID Solicitation Read More »

Court Blocks NIH Cap Indirect Cost Rate

Court Blocks NIH Cap on Indirect Cost Rates

Leave a Comment / All Posts, Life Sciences, NIH / By

Court Blocks NIH Cap on Indirect Cost Rates for Government Contracts In a significant development for research institutions and federal contractors, a federal judge has temporarily blocked the National Institutes of Health (NIH) from enforcing its cap on indirect cost rates. This decision comes as a result of a temporary restraining order (TRO) issued by

Court Blocks NIH Cap on Indirect Cost Rates Read More »

NIH Supplemental Guidance

Understanding the NIH Supplemental Guidance on Indirect Cost Rates

Leave a Comment / All Posts, Life Sciences, NIH / By

Overview The National Institutes of Health (NIH) has issued Supplemental Guidance to the 2024 NIH Grants Policy Statement regarding Indirect Cost Rates (NOT-OD-25-068). This update introduces a standardized 15% indirect cost rate for all applicable grants, aiming to streamline financial policies and enhance funding efficiency for research institutions. Purpose of the Guidance The primary objective

Understanding the NIH Supplemental Guidance on Indirect Cost Rates Read More »

US Capitol building silhouette on blue paint texture

Review of Federal Funding: What It Means and What Comes Next for Life Sciences Organizations

Leave a Comment / All Posts, Life Sciences / By

On January 27 and January 28, the Office of Management and Budget (OMB) issued guidance as follows: Memorandum M-25-13, an executive directive halting all federal financial assistance programs as agencies reevaluate spending priorities. An Excel file titled Federal Financial Assistance Program Analysis Template Additional Guidance with Q&A OMB Memorandum M-25-13 Published on January 27, 2025,

Review of Federal Funding: What It Means and What Comes Next for Life Sciences Organizations Read More »

antiviral therapeutics against filoviruses

New Opportunities with DRIVe: ReBooT and RePAIR Amendments

Leave a Comment / All Posts, BARDA, Life Sciences / By

Amendment 034 – DRIVe EZ BAA_ReBooT_RePAIR New Opportunities with DRIVe: ReBooT and RePAIR Amendments The Biomedical Advanced Research and Development Authority’s (BARDA) Division of Research, Innovation & Ventures (DRIVe) has announced updates to its Easy Broad Agency Announcement (EZ-BAA) with Amendment #034. This amendment reopens and revises the ReBooT (AOI #22) program and pauses the

New Opportunities with DRIVe: ReBooT and RePAIR Amendments Read More »

ARPA-H_EIH health and biomedical research

Emerging Health Innovators (EHI) Initiative

Leave a Comment / All Posts, ARPA-H, Life Sciences / By

ARPA_H_SOL_25_118_EHI_Solicitation (1) Emerging Health Innovators Solicitation: An Opportunity to Revolutionize Health Innovation The Advanced Research Projects Agency for Health (ARPA-H) has issued the Emerging Health Innovators (EHI) Initiative Solicitation (ARPA-H-SOL-25-118), a groundbreaking funding opportunity aimed at empowering both early-career researchers and community innovators to advance health and biomedical research. Through the EHI Initiative, ARPA-H seeks

Emerging Health Innovators (EHI) Initiative Read More »

MTEC RPP medical techniques, knowledge products, and materials

EverGlade Consulting Funding Alert: MTEC Fiscal Year 2025 Multi-Topic Request for Project Proposals

Leave a Comment / All Posts, Life Sciences, MTEC / By

MTEC-25-04-MultiTopic-RPP_Final Overview of the Solicitation The Medical Technology Enterprise Consortium (MTEC) has recently announced its Fiscal Year 2025 Multi-Topic Request for Project Proposals (RPP). This RPP focuses on eleven key Focus Areas to stimulate innovative medical prototype, technological, and knowledge solutions with military relevance. The RPP targets the following focus areas: Focus Area 1 –

EverGlade Consulting Funding Alert: MTEC Fiscal Year 2025 Multi-Topic Request for Project Proposals Read More »

ARPA-H, RAPID Funding Alert

EverGlade Consulting Funding Alert: Proposer’s Day for Rare disease AI/ML for Precision Integrated Diagnostics (RAPID)

Leave a Comment / All Posts, ARPA-H, Life Sciences / By

RAPID_Special_Notice ARPA-H’s RAPID Program The Advanced Research Projects Agency for Health (ARPA-H) recently announced the newly approved program for Rare disease AI/ML for Precision Integrated Diagnostics (RAPID). This initiative aims to revolutionize the prolonged diagnostic odyssey faced by millions of rare disease patients worldwide. Utilizing fragmented datasets and state-of-the-art technologies, RAPID aims to democratize access

EverGlade Consulting Funding Alert: Proposer’s Day for Rare disease AI/ML for Precision Integrated Diagnostics (RAPID) Read More »

Scroll to Top